Share this link via:
1.1 Global Anti-Sortilin Monoclonal Antibody Market Snapshot
1.2 Market Size & Forecast Analysis (2022–2034)
1.3 Key Growth Drivers, Restraints & Opportunities
1.4 Clinical Development & Commercialization Outlook
1.5 Biomarker-Driven Precision Medicine Overview
1.6 Competitive Positioning of Key Pipeline Candidates
1.7 Regional Opportunity Assessment
1.8 Analyst Recommendations & Strategic Insights
2.1 Overview of Sortilin (SORT1) Biology
2.2 Role of Sortilin in Lysosomal Function & Protein Trafficking
2.3 Progranulin Regulation Mechanism
2.4 Therapeutic Rationale for Sortilin Blockade
2.5 Anti-Sortilin Antibody Technology Evolution
2.6 Blood-Brain Barrier Challenges in CNS Antibody Therapy
2.7 Comparison with Other Neurodegenerative Therapeutic Approaches
2.8 Future Potential of SORT1-Targeted Therapies
3.1.1 Rising Unmet Need in Frontotemporal Dementia (FTD-GRN)
3.1.2 Expansion of Precision Neurology & Biomarker Medicine
3.1.3 Increasing Regulatory Support for Rare Neurological Disorders
3.1.4 Growth in Genetic Testing & Early Diagnosis Infrastructure
3.1.5 Advancements in CNS-Focused Biologic Engineering
3.2.1 Early-Stage Clinical Development Risks
3.2.2 Limited CNS Penetration of Monoclonal Antibodies
3.2.3 Small Addressable Patient Population in Rare Indications
3.2.4 High Manufacturing & Development Costs
3.2.5 Reimbursement Uncertainty for Premium Neurology Biologics
3.3.1 Expansion into Alzheimer’s Disease Applications
3.3.2 Parkinson’s Disease & ALS Therapeutic Potential
3.3.3 Bispecific Antibody Development for BBB Penetration
3.3.4 Combination Therapy Strategies
3.3.5 Companion Diagnostics & Biomarker Commercialization
3.4.1 Translational Gap Between Biomarker Improvement & Clinical Outcomes
3.4.2 Long Neurodegenerative Clinical Trial Timelines
3.4.3 Patient Recruitment Challenges in Rare Genetic Disorders
3.4.4 Regulatory Complexity for Biomarker-Based Approvals
4.1 Discovery & Target Validation
4.2 Antibody Engineering & Optimization
4.3 Preclinical CNS Evaluation
4.4 Clinical Development Ecosystem
4.5 Biomarker & Companion Diagnostic Development
4.6 Biologics Manufacturing & Supply Chain
4.7 Regulatory & Market Access Framework
4.8 Commercial Distribution Channels
5.1 Current Anti-Sortilin Clinical Pipeline Overview
5.2 Phase I Clinical Programs
5.3 Phase II Clinical Programs
5.4 Phase III Clinical Programs
5.5 Next-Generation Bispecific Platforms
5.6 Antibody-Drug Conjugate Strategies
5.7 CNS Delivery Enhancement Technologies
5.8 Companion Diagnostic & Biomarker Platforms
5.9 Comparative Analysis of Pipeline Candidates
6.1 FDA Regulatory Framework for Rare Neurological Disorders
6.2 EMA Orphan Drug & Conditional Approval Pathways
6.3 Breakthrough Therapy & Fast Track Designations
6.4 Biomarker-Based Accelerated Approval Strategies
6.5 Reimbursement Trends in Neurology Biologics
6.6 Health Technology Assessment Considerations
6.7 Pricing & Market Access Dynamics
6.8 Intellectual Property & Exclusivity Analysis
7.1 Fully Human Monoclonal Antibodies
7.2 Humanized Monoclonal Antibodies
7.3 Bispecific Antibodies
7.4 Antibody-Drug Conjugates
7.5 Next-Generation Engineered Antibody Formats
8.1 Frontotemporal Dementia (FTD-GRN)
8.2 Alzheimer’s Disease
8.3 Parkinson’s Disease & Lewy Body Dementia
8.4 Amyotrophic Lateral Sclerosis (ALS)
8.5 Cardiovascular Disease Applications
8.6 Oncology Applications
9.1 GRN Mutation Carriers
9.2 Progranulin-Deficient Populations
9.3 SORT1 Genetic Variant Populations
9.4 Sporadic Neurodegenerative Disease Cohorts
9.5 Biomarker-Enriched Patient Subgroups
10.1 Progranulin Elevation Through Sortilin Blockade
10.2 Lysosomal Function Restoration
10.3 Neuroinflammation Modulation
10.4 PCSK9 Pathway Regulation
10.5 Multi-Mechanistic Neuroprotective Strategies
11.1 Intravenous Infusion
11.2 Subcutaneous Injection
11.3 Long-Acting Delivery Systems
11.4 Self-Administration Technologies
12.1 Academic Medical Centers
12.2 Neurology Specialty Clinics
12.3 Hospitals & Health Systems
12.4 Contract Research Organizations
12.5 Genetic Counseling Centers
13.1 North America
13.1.1 United States
13.1.2 Canada
13.2 Europe
13.2.1 Germany
13.2.2 United Kingdom
13.2.3 France
13.2.4 Italy
13.2.5 Spain
13.2.6 Switzerland
13.2.7 Netherlands
13.3 Asia Pacific
13.3.1 Japan
13.3.2 China
13.3.3 South Korea
13.3.4 Australia
13.4 Middle East & Africa
13.4.1 UAE
13.4.2 Saudi Arabia
13.4.3 South Africa
13.5 Latin America
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Argentina
14.1 Market Structure & Competitive Benchmarking
14.2 Pipeline Positioning Analysis
14.3 Strategic Collaborations & Licensing Agreements
14.4 Mergers, Acquisitions & Investment Trends
14.5 Clinical Development Benchmarking
14.6 Technology Differentiation Analysis
14.7 Patent Landscape Assessment
14.8 SWOT Analysis of Leading Companies
15.1 Alector Inc.
15.2 AstraZeneca PLC
15.3 GSK plc
15.4 Denali Therapeutics Inc.
15.5 AC Immune SA
15.6 Arkuda Therapeutics
15.7 Prevail Therapeutics
15.8 Biogen Inc.
15.9 Regeneron Pharmaceuticals Inc.
15.10 Amgen Inc.
15.11 UCB SA
15.12 Lundbeck A/S
15.13 BioArctic AB
15.14 Vigil Neuroscience Inc.
You'll get the sample you asked for by email. Remember to check your spam folder as well. If you have any further questions or require additional assistance, feel free to let us know via-
+1 724 648 0810 +91 976 407 9503 sales@intellectualmarketinsights.com
20 May 2026
Intellectual Market Insights Research © 2026. All rights reserved.
